Vor Biopharma (VOR) Corporate presentation summary

Strategic ambition and financial position

• Aims to transform treatment of B cell-driven autoimmune diseases with a selective BAFF/APRIL inhibitor, telitacicept.

• Telitacicept is clinically validated in over eight autoimmune indications in China, with tens of thousands of patients treated.

• Maintains a strong cash position of ~$515M as of June 2026, with runway into early 2029 to fund key milestones.

Mechanism of action and clinical differentiation

• Telitacicept is a TACI-Fc fusion protein that inhibits both BAFF and APRIL, targeting autoreactive B cells and plasma cells.

• Preferentially depletes pathogenic cells while preserving humoral immunity, reducing autoantibodies more than total IgG.

• Demonstrates manageable safety and tolerability, with no burdensome vaccination requirements or signature B cell depletion-associated serious adverse events.

Clinical efficacy and safety in myasthenia gravis (MG)

• Phase 3 trial in China showed telitacicept delivered a 4.8-point MG-ADL and 6.4-point QMG separation from placebo, the largest reported in gMG.

• Sustained and deepening functional improvement observed through 48 weeks, with high responder rates.

• Consistent reduction in IgG, IgA, IgM, and B cells, addressing broader autoantibody profiles than current therapies.

• Favorable safety profile consistent with other autoimmune indications and post-marketing data.